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Abstract
BACKGROUND: Coronavirus current pandemic (COVID-19) is the striking subject worldwide hitting countries in 
an unexplained non-universal pattern. Bacillus Calmette–Guérin (BCG) vaccine was an adopted recent justification 
depending on its non-specific immune activation properties. Still the problem of post-vaccine short duration of 
protection needs to be solved. The same protective mechanism was identified in active or latent tuberculosis (TB). 
For each single patient of active TB, there are about nine cases of asymptomatic latent TB apparently normal 
individuals living within the community without restrictions carrying benefits of immune activation and involved in 
re-infection cycles in an excellent example of repeated immunity training sessions of the whole community. 
AIM: We aimed to asses the correlation between TB burden and COVID-19 mortality in all affected countries having 
different BCG vaccination policies. 
METHODS: Publicly available data were extracted for 191 countries including population size, TB estimations, 
national BCG vaccination policy, the World Health Organization regions and economic classification, and COVID-19 
mortality and number of cases. The analysis was performed using Spearman’s correlation test.
RESULTS: Significant large negative correlation (−0.539, p < 0.001) was found between TB prevalence and 
COVID-19 mortality rate worldwide. Medium negative significant correlations were found between TB cases and 
COVID-19 mortality in the high and lower middle-income countries, and those having current BCG vaccination 
programs (−0.395, p = 0.001, −0.365, p = 0.015, and −0.476, p < 0.001, respectively).
CONCLUSION: Countries with high TB prevalence have higher chances of protection against COVID-19 mortality 
through the theory of widely distributed natural immune activation within community. Confounders should be 
assessed separately.
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Introduction
Less than 3 months were needed for the World 
Health Organization (WHO) to declare coronavirus 
disease (COVID-19) pandemic on March 11, 2020, 
since the first cases appeared in Wuhan, China in 
December, 2019. At that point of the WHO statement, 
the disease was found in more than 110 countries all 
over the world. Up to the time of preparing this article, 
on July 13, 2020; over 12,685,374 people were infected 
in 216 countries and territories worldwide, with more 
than 565,000 patients died [1].
The speed of infection and mortality has 
shown differential models in various countries, United 
States has the bigger share globally, while Italy and 
Spain in Europe and Iran and India in Asia did the 
same within their continents. The number of confirmed 
cases in a country depends on many factors such as 
the availability of the diagnostic tests, efficiency of 
screening programs, and people’s cooperation [1], [2].
Mortality rates differ among countries, 
although the health infrastructure potency is a vital 
issue, older patients ≥65 years are the main target. 
Furthermore, comorbidities such as cardiac, renal, liver, 
and hematological illnesses, on admission D-dimer 
elevations, and social habits such as smoking were 
within reported risks. Immunological defects in cellular 
immunity of T and B cells along with later escalation of 
cytokine cells type 2 productions have the major role 
toward failure of control over viral replication leading to 
heavier inflammation and damage, especially in ACE 2 
receptors rich organs such as kidneys and lungs with 
net result of poorer fates [3], [4].
Mycobacterium tuberculosis (Mtb) micro-
organisms cause tuberculosis (TB) infection which is 
a common disease worldwide with a clear focus into 
countries having low and middle-income. One out of 
four humans on earth is diseased with TB, only 5–15% 
of them have symptoms and active illness, so that about 
90% do not show the disease where the host immune 
response contained Mtb resulting in a condition called 
latent tuberculosis (LTB). Most of these LTB individuals 
are missed and living within the community as normal 
people having the advantage of lifelong immune system 
activation which starts with innate response aided 
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by macrophages and dendritic cells, then T-cellular 
immune activation will come afterward, especially CD4 
and eight, in addition to cytokines distinct role [5], [6].
Trying to take control over the widely-distributed 
TB disease, a vaccine was developed in the form of 
live attenuated mycobacterium bovis, called Bacillus 
Calmette–Guérin (BCG) which has a similar approach 
of immune stimulation caused by LTB infection including 
cellular and humeral immune response. This training 
exercise for the natural immunity either caused by the 
vaccine or the TB disease itself would offer a protection 
not limited to Mtb, but extended to other viral infections 
and respiratory illnesses [7], [8].
Herein, this study; influenced by the distinct 
protective benefits of the non-specific activation of 
immune system, we evaluated the association between 
TB prevalence and mortality rates in different countries 
affected by COVID-19 pandemic, in the presence or 
absence of BCG vaccination programs.
Methods
Available data on public domains for both 
COVID19 and TB for 191 countries were collected and 
analyzed. Population size, number of TB cases, and the 
WHO regions were obtained from the WHO databases 
along with the classification of economic classes. Data 
about BCG vaccination policy were obtained from 
TB world atlas available at (http://www.bcgatlas.org/
index.php. Accessed on July 13, 2020). Data about 
COVID-19 number of cases and death were obtained 
from worldometer website available at (https://www.
worldometers.info/coronavirus/. Accessed on July 13, 
2020). Spearman’s correlation test was used for the 
postulated correlation.
It is noteworthy to mention that we could not 
control for possible confounding factors including life 
expectancy, proportion of elderly among population, 
country preparedness, age, gender, ethnicity, onset of 
epidemic, migration rate, precision of reporting, and 
population density.
Results
We tried not to miss any country in the 
world registered by the WHO in our analysis. Table 1 
shows significant large negative correlation between 
COVID-10 death rate and TB incidence rate per 100 K 
population.
Among high income and lower middle-income 
countries, there is a significant medium negative correlation 
between COVID-19 death rate and TB incidence rate per 
100 K population, as illustrated in Table 2.
Table 2: Relationship between TB cases and current 
coronavirus mortality rate according to economic level
Economic class Number of countries Correlation (R) p value
High 66 −0.395 0.001
Low 27 −0.161 0.423
Lower medium 44 −0.365 0.015
Upper medium 52 −0.031 0.826
There is a significant medium negative 
correlation between coronavirus pandemic death rate 
and TB incidence rate per 100 K population in countries 
with current BCG vaccination programs. These findings 
are clear in Table 3.
Table 3: Correlation between rates of TB incidence and 
COVID-19 mortality with regard to BCG vaccination status
BCG vaccination status Number of countries Correlation (R) p value
Current 151 −0.476 <0.001
No 19 −0.299 0.213
Previous 21 −0.332 0.141
Discussion
Of interest; COVID-19 spread, morbidity and 
mortality varied widely within various countries, which 
may be attributed to differences in background culture, 
health system programs, and migration movements. 
Scientists all around the globe are racing against time 
to understand the pathophysiology and behavior of this 
viral infection aiming to discover a vaccine or proper 
treatment plan. Theories were proposed along the way, 
many of them focused on the immune system as the 
primary defense mechanism against the virus attack.
Accordingly, BCG vaccination was recently put 
on the table as an immune stimulant to explain the low 
incidence rates of COVID-19 in countries with routine 
BCG vaccination practice [8].
This possibility of BCG vaccine could not stand 
hard in many countries with BCG immunization and high 
rates of COVID-19 mortality and morbidity providing 
that the post-BCG vaccine duration of protection has 
been thought to last only about 10 years [9], although 
a single report suggested a substantial protection for a 
longer time [10].
Moreover; some scientists recommended to 
repeat BCG at any time after at least 3 months’ post-
vaccination because peripheral BCG-induced T-cell 
memory (effector) population could wane between 
3 and 12 months in contrast to central T-cell memory 
which might persist for decades [11], [12].
All these previously-mentioned BCG related 
parameters would make it difficult to rely only on 
Table 1: Worldwide TB cases related to current coronavirus 
prevalence and mortality
Overall Number of countries Correlation (R) p value
COVID-19 versus TB cases 191 0.153 0.035
COVID-19 death versus TB rate 191 −0.539 <0.001
 Al-Momen et al. COVID-19 mortality and Tuberculosis
Open Access Maced J Med Sci. 2020 Sep 25; 8(T1):179-183. 181
vaccination data to explain COVID-19 cases as they are 
usually clustered in older age groups where BCG effects 
might have been weakened or even disappeared.
Based on the above, we tried something 
different through focusing on the possible impacts of 
TB prevalence in affected countries which mirrors the 
large sector of population carrying latent TB infection 
when ice burg phenomenon is applied [1], [2].
So that, if one individual has the diagnosis of 
active TB infection, there has been about nine other 
people with latent TB diffused within the community 
and usually unnoticed having the advantage of lifelong 
immune system stimulation on the contrary of the 
vaccine where its immune modulation protective effects 
are vanished with time [9], [10], [11], [12].
We assumed that countries with high TB 
prevalence have a large population percentage of latent 
TB individuals whom represent a continuous source of 
infection and re-infection cycles (mostly asymptomatic) 
within the community giving it a good chance of ongoing 
training drills to the immune system making most people 
resistant to infection complications (including death), a 
situation which is known as herd immunity [13].
According to our data analysis, we found 
out a very significant protective (negative) correlation 
(−0.539, p < 0.001) between TB number of cases and 
COVID-19 mortality rate throughout the world. This 
crude correlation confirms our above assumption.
Some areas in the world were heavily attacked 
by COVID-19 leaving more deaths every day. Europe 
and United States (US) were the major targets of this 
pandemic regarding deaths per 1 million of population 
based on worldometer website available at (https://
www.worldometers.info/coronavirus/. Accessed on July 
13, 2020). This confusing and unexplained matter urged 
us to look into each country on earth after dividing them 
according to the WHO income classification, regarding 
TB prevalence and COVID-19 death rates. A medium 
statistically significant protective correlation appeared 
in high income countries including Europe and US, and 
low middle-income countries (−0.395, p =0.001, −0.365, 
p = 0.015, respectively). A preceding work suggested 
higher COVID-19 incidence and death rate in high 
versus medium economic stage countries based on 
GDP (gross domestic production) per capita. Most high-
income countries have higher means of population age, 
and dramatic decrease in TB cases in the community 
with more hygienic environment that necessitating non-
routine use of BCG vaccination [14] which, in turn, might 
increase COVID-19 burden following our assumption.
According to the WHO estimations 
available at (https://www.who.int/health-topics/
tuberculosis#tab=tab_1. Accessed on July 13, 2020), 
half of TB cases in the world were concentrated in eight 
countries, six of them are low middle-income countries 
including Bangladesh, India, Pakistan, Indonesia, 
Nigeria, and the Philippines.
At this point, we tried to investigate the already 
published hypothesis of non-specific BCG vaccination 
protection effects through immune stimulation; we 
divided countries on the basis of vaccination status. 
Current BCG vaccination seemed to have medium 
protection significant effects to translate the link between 
high TB prevalence and low COVID-19 mortality.
Most countries with current BCG according 
to TB world atlas available at (http://www.bcgatlas.
org/index.php. Accessed on July 13, 2020) have high 
TB burden which might be one of the causes that 
pushed such countries to keep on the continuity of 
BCG programs. Based on our presumed opinion, it is 
easy to judge if that low rates of mortality of current 
coronavirus infection were due to short-term immune 
activation resulted from BCG vaccine or the natural 
asymptomatic infection cycles within the community 
aided by latent TB.
Some reports suggested that countries with 
up to date continuous BCG immunization programs 
did better than countries with interrupted or irregular 
national vaccination policy. Italy and US were good 
examples of high COVID-19 mortality while they did not 
experience universal vaccination programs throughout 
their history [15]. This could be explained by the above-
mentioned observation of low TB cases in countries 
without universal BCG vaccination as simply they did 
not need it.
This was also confirmed by another article 
which claimed that countries with regular present BCG 
vaccination had better outcomes than countries with 
the previous or nil vaccination policy [16].
Flattening of incidence and mortality curves 
of coronavirus pandemic at each country officially 
ordering BCG vaccination within a month from the 
beginning of the wide spread, depending on the distinct 
correlation between universal BCG policy and COVOD-
19 prevalence was the findings declared by more 
researchers [17], [18].
Our data did not show significant effects 
of the previous BCG vaccination on correlation 
between TB prevalence and COVID-19 deaths. This 
is expected according to our hypothesis as it is logical 
for countries having low TB prevalence to re-evaluate 
their vaccination strategy and decide to stop BCG, 
confirming our idea of low TB cases (including latent 
TB) would leave the community immunity status without 
activation exercises while early vaccination could not 
help because of limited protection time. Spain is an 
example with the previous vaccination policy having 
one of the highest mortality rates worldwide (deaths 
per 1 million of population) according to worldometers 
website available at (https://www.worldometers.info/
coronavirus/. Accessed on July 13, 2020).
This was agreed by other scientists who 
investigated BCG national coverage during 1 year of 
age from 1980 to 1985 to find out no significant effects 
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on COVID-19 burden [19]. In addition, timing of BCG 
was not an important risk factor for COVID-19 spread 
as revealed by some writers [8].
A preceding paper suggested a re-vaccination 
strategy [20]. Again, this could confirm our idea which 
says that latent TB could put the community immune 
system in an alert mode because of high theoretical 
possibility of continuous infection vicious circles 
occurred in a natural way in contrast to BCG.
A fresh Japanese paper suggested the protective 
role of cellular immunity in COVID-19 severity [21]. 
Although latent TB immune activation is non-specific, 
cellular immunity is a major participant [7], [8].
It is worthy to say that although concerns were 
present especially in developed world about latent 
TB with a potential risk of activation [22], and specific 
theoretical worries about TB patients when catch 
COVID-19 infection [23], based on a single retrospective 
Chinese article that involved only two patients with 
latent TB but no details of their clinical history [24], there 
is a clear evidence that latent TB cases represent the 
immune reactive stage and most of them do not convert 
into active TB disease even when immune suppressive 
circumstances have been experienced in line with our 
alleged consideration [25].
However, many confounding factors could 
play a role in the mortality or even spread of COVID-
19 leading to different trajectories in different countries, 
such as but not limited to fast and effective general 
protective measures including social crowdedness 
prevention, biological and genetic factors, presence of 
comorbidities and chronic illnesses, and environmental 
pollution, and prevalence of other respiratory viral 
infections such as different species of influenza virus, 
and national vaccination program including other 
vaccines, preparedness of local health system, and 
pandemic COVID-19 curve stage in each country. 
Some of these confounders were studied or suggested 
to be evaluated by the previous workers [8], [14].
We did not involve number of COVID-19 cases 
in our data analysis due to two main reasons, first 
because of differences in accuracy levels of COVID-
19 registry systems in different countries depending 
on available resources, second cause based on our 
hypothesis of immune protection offered by latent TB 
which affects the severity of the disease (COVID-19) 
rather than the incidence, that is, to say if patients have 
good immunity, the infection is expected to follow a mild 
course which may be represented by low mortality.
Conclusion
Tuberculosis burden has a distinctive crude 
effect on COVID-19 mortality through our assumption 
of immune activation theory which is somewhat 
close to BCG vaccination mechanism but with longer 
duration resulting in more effective protection against 
potential lethal nature of current coronavirus pandemic. 
Confounding factors should be evaluated through 
controlled clinical trials [26].
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